plerixafor

ROUTE	ONSET	PEAK	DURATION
SUBQ	rapid	10–14 hr*	unknown

Contraindicated in:

Hypersensitivity;
Leukemia;
OB: Pregnancy;
Lactation: Lactation.

Use Cautiously in:

Renal impairment (dose ↓ required if CCr ≤50 mL/min);
Rep: Women of reproductive potential and men with female partners of reproductive potential;
Pedi: Safety and effectiveness not established in children;
Geri: Consider age-related ↓ in renal function and greater sensitivity to drug effects in older adults.

Adv. Reactions/Side Effects ⬆ ⬇

Derm: erythema, sweating

GI: diarrhea, nausea, vomiting, abdominal distention/pain, constipation, dry mouth, dyspepsia, flatulence, splenic enlargement, SPLENIC RUPTURE

Hemat: leukemia/tumor cell mobilization, thrombocytopenia

Local: injection site reactions

MS: musculoskeletal pain

Neuro: dizziness, fatigue, headache, insomnia, oral hypoesthesia

Misc: HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS)

Interactions ⬆ ⬇

Drug-drug:

None reported.

Route/Dosage ⬆ ⬇

SC (Adults >83 kg): Following pretreatment with G-CSF for 4 days: 0.24 mg/kg once daily given 11 hr prior to each apheresis and continued for up to 4 days (not to exceed 40 mg/day); use actual body weight to calculate dose.
SC (Adults ≤83 kg): Following pretreatment with G-CSF for 4 days: 0.24 mg/kg or 20 mg once daily given 11 hr prior to each apheresis and continued for up to 4 days; use actual body weight to calculate dose.

Renal Impairment

SC (Adults 84–159 kg): Following pretreatment with G-CSF for 4 days (CCr ≤50 mL/min): 0.16 mg/kg once daily given 11 hr prior to each apheresis and continued for up to 4 days (not to exceed 27 mg/day).

Renal Impairment

SC (Adults ≤83 kg): Following pretreatment with G-CSF for 4 days (CCr ≤50 mL/min): 0.16 mg/kg or 13 mg once daily given 11 hr prior to each apheresis and continued for up to 4 days.

Availability ⬆ ⬇

(Generic available)

Solution for injection: 24 mg/1.2 mL

Assessment ⬆ ⬇

Assess for splenic enlargement and potential rupture (left upper abdominal pain and/or scapular or shoulder pain) periodically during therapy.
Monitor for signs and symptoms of anaphylaxis (urticaria, periorbital swelling, dyspnea, hypoxia) during and for at least 30 min following administration. Discontinue therapy and treat symptomatically if symptoms occur.

Lab Test Considerations:

Obtain a negative pregnancy test before starting therapy.
- Monitor WBC and platelets during therapy. May cause leukocytosis and thrombocytopenia.

Implementation ⬆ ⬇

Begin therapy after patient has received 4 days of G-CSF daily and approximately 11 hr prior to initiation of apheresis.
SC: Administer SUBQ daily for 4 days. Solution is clear, colorless to pale yellow; do not use solutions that are cloudy, discolored, or contain a precipitate. Vials are single use; discard any unused medication.

Patient/Family Teaching ⬆ ⬇

Explain purpose of medication to patient.
Advise patient to notify health care professional if signs and symptoms of systemic reactions (urticaria, periorbital swelling, dyspnea, hypoxia) or splenic rupture (left upper abdominal pain and/or scapular or shoulder pain) occur.
Instruct patient to notify health care professional immediately if vasovagal reactions (orthostatic hypotension, syncope) occur during or shortly after injection.
Advise patient to notify health care professional if itching, rash, or reactions at injection site occur; may be treated with OTC medications.
May cause GI disorders (diarrhea, nausea, vomiting, flatulence, abdominal pain). Advise patient to notify health care professional if GI disorders are severe.
Rep: May cause fetal harm. Caution females of reproductive potential to use effective contraception and to avoid breastfeeding during and for 1 wk after final dose of therapy. Caution males with female partners of reproductive potential to use effective contraception during and for 1 wk after final dose of therapy. Advise patient to notify health care professional if pregnancy is planned or suspected.

Evaluation/Desired Outcomes ⬆ ⬇

Mobilization of stem cells to peripheral blood allowing collection.

US Brand Names ⬆ ⬇

Code ⬆

NDC Code

0024- sanofi-aventis U.S. LLC
- 0024-5862- Mozobil
  - 0024-5862-01- 1 VIAL, SINGLE-USE in 1 CARTON (0024-5862-01) / 1.2 mL in 1 VIAL, SINGLE-USE

0480- Teva Pharmaceuticals, Inc.
- 0480-4320- Plerixafor
  - 0480-4320-01- 1 VIAL, SINGLE-DOSE in 1 CARTON (0480-4320-01) / 1.2 mL in 1 VIAL, SINGLE-DOSE

25021- Sagent Pharmaceuticals
- 25021-416- Plerixafor
  - 25021-416-01- 1 VIAL in 1 CARTON (25021-416-01) / 1.2 mL in 1 VIAL

42973- Apicore Pharmaceuticals Private Limited
- 42973-202-
  - 42973-202-00- 50 kg in 1 DRUM (42973-202-00)

43598- Dr. Reddy's Laboratories Inc
- 43598-308- Plerixafor
  - 43598-308-23- 1 VIAL, SINGLE-DOSE in 1 CARTON (43598-308-23) / 1.2 mL in 1 VIAL, SINGLE-DOSE

54893- MSN Laboratories Private Limited
- 54893-0050-
  - 54893-0050-6- 3 kg in 1 DRUM (54893-0050-6)

55111- Dr.Reddy's Laboratories Limited
- 55111-954-
  - 55111-954-00- 1 kg in 1 DRUM (55111-954-00)

55150- Eugia US LLC
- 55150-356- Plerixafor
  55150-356-01- 1 VIAL, SINGLE-DOSE in 1 CARTON (55150-356-01) / 1.2 mL in 1 VIAL, SINGLE-DOSE

65219- Fresenius Kabi Usa, LLC
- 65219-284- Plerixafor
  - 65219-284-12- 1 VIAL, SINGLE-USE in 1 CARTON (65219-284-12) / 1.2 mL in 1 VIAL, SINGLE-USE

68083- Gland Pharma Limited
- 68083-155- Plerixafor
  - 68083-155-01- 1 VIAL in 1 CARTON (68083-155-01) / 1.2 mL in 1 VIAL

68554- Hetero Labs Limited
- 68554-0067-
  - 68554-0067-1- .45 kg in 1 DRUM (68554-0067-1)

70121- Amneal Pharmaceuticals LLC
- 70121-1694- plerixafor
  70121-1694-2- 1 VIAL, SINGLE-DOSE in 1 CARTON (70121-1694-2) / 1.2 mL in 1 VIAL, SINGLE-DOSE

70710- Zydus Pharmaceuticals USA Inc.
- 70710-1208- PLERIXAFOR
  - 70710-1208-1- 1 VIAL, SINGLE-USE in 1 CARTON (70710-1208-1) / 1.2 mL in 1 VIAL, SINGLE-USE

70771- Zydus Lifesciences Limited
- 70771-1776- PLERIXAFOR
  - 70771-1776-1- 1 VIAL, SINGLE-USE in 1 CARTON (70771-1776-1) / 1.2 mL in 1 VIAL, SINGLE-USE

71288- Meitheal Pharmaceuticals Inc.
- 71288-155- Plerixafor
  - 71288-155-01- 1 VIAL, SINGLE-DOSE in 1 CARTON (71288-155-01) / 1.2 mL in 1 VIAL, SINGLE-DOSE

72205- Novadoz Pharmaceuticals LLC
- 72205-249- Plerixafor
  - 72205-249-01- 1 VIAL, SINGLE-DOSE in 1 CARTON (72205-249-01) / 1.2 mL in 1 VIAL, SINGLE-DOSE

76055- Sionc Pharmaceutical Private Limited
- 76055-0017-
  - 76055-0017-1- 25 kg in 1 DRUM (76055-0017-1)

section name header

Pronunciation ⬇

Classifications ⬆ ⬇

Indications ⬆ ⬇

Action ⬆ ⬇

Pharmacokinetics ⬆ ⬇

Time/Action Profile ⬆ ⬇

Contraind./Precautions ⬆ ⬇